Digital AI in drug development: The real hurdle is implementation Web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn.AI, about effectively implementing AI.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.